Contract development and manufacturing (CDMO) in Singapore
- On the record
- 9
- Governing standards
- PIC/S GMP; FDA/EMA/HSA inspection track record
- Sector
- Biomedical & Medtech Manufacturing
Contract process development and GMP production of medicines for pharma and biotech clients that lack their own plants or want to flex capacity.
Buyers select on modality coverage, stage from preclinical and clinical material to commercial supply, capacity and technology, and FDA, EMA and HSA regulatory track record. The companies on the record holding this capability are collected on the Singapore Industry Index’s lists of Leading pharmaceutical companies in Singapore and Leading contract manufacturers in Singapore.
A CDMO makes other companies' medicines — a contract development and manufacturing organisation sells process development and GMP production capacity to pharma and biotech clients who lack their own plants or want to flex capacity. It is the fastest-growing structural layer of Singapore's drug-making economy, and the one that turns the country's regulatory credibility and Tuas Biomedical Park land into a tradable service. The signature project is WuXi Biologics' roughly US$1.4 billion integrated CRDMO on a 13.5-hectare Tuas site, adding 120,000 litres of biologics capacity and about 1,500 jobs as an end-to-end drug-substance-and-product hub; alongside it, Lonza runs a long-established mammalian CDMO campus and Thermo Fisher/Patheon operates a 24,000 m² sterile fill-finish CDMO at Joo Koon. The buyer here is a client company, and the record's job is to distinguish the firms that genuinely manufacture-for-hire in Singapore from the sales offices and R&D labs that do not.
The buyer's decision stack runs on modality coverage (mAbs, recombinant proteins, ADCs/bioconjugates, plasmid DNA, viral vector, cell therapy, small molecule); stage (preclinical and clinical material through to commercial and BLA-enabling supply); capacity and technology (single-use versus stainless-steel, bioreactor scale, fill-finish and lyophilisation); and regulatory track record with FDA/EMA/HSA. The field is a barbell of global CDMO majors — WuXi Biologics, Lonza, Thermo Fisher/Patheon, and the ADC specialist WuXi XDC — and a homegrown / mid-tier anchored by Esco Aster (a genuinely Singaporean CDMO spanning viral vector, cell therapy, plasmid DNA and small-batch aseptic fill) and Hilleman Laboratories (multi-modality vaccine/biologics development-and-manufacturing), with finished-dose contract capacity from local pharma makers Beacons and ICM Pharma. The structural driver is the global outsourcing of biologics and advanced-therapy production, and Singapore's bid to be the region's trusted GMP address for it.
Companies with this capability in Singapore
Listed alphabetically. Order does not indicate ranking.
A roughly 2,000 m2 GMP cell-therapy facility on the Singapore General Hospital campus with 14 clean suites, 4 translational labs and a QC lab, enabling hospitals, research institutions and biotech startups to carry out cell selection, genetic modification and manufacture of cell therapies locally — a national shared-GMP facility.
A homegrown manufacturer described as Singapore's largest generic-pharmaceutical maker, producing 200-plus therapeutics across multiple finished dosage forms from two PIC/S-GMP plants, with fully integrated contract manufacturing.
A homegrown Singapore CDMO at Ayer Rajah Crescent offering biologics, viral-vector production, cell-therapy manufacturing on its proprietary Tide Motion bioreactor platform, plasmid-DNA manufacturing and small-batch aseptic fill-finish — positioned as Southeast Asia's first small-batch aseptic fill-and-finish service — with an A*STAR bioprocessing partnership.
A roughly US$20 million, ~30,000 sq ft multi-modality vaccine-and-biologics development-and-manufacturing facility at Depot Road (the ACES facility) with end-to-end drug-substance, drug-product and clinical-material capability in isolated single-use suites, focused on mRNA and viral-vector platforms through Phase II; billed as Singapore's only multi-modality vaccine-and-biologics development-and-manufacturing organisation.
A Singapore finished-dose manufacturer producing 300-plus products across tablets, capsules, liquids, creams and injectables at a cGMP facility, with contract and OEM manufacturing via its PharmaKoe arm.
A large mammalian cell-culture CDMO campus at Tuas producing monoclonal antibodies and recombinant and fusion proteins across 20,000-litre stainless-steel and 2,000-litre single-use suites, with cell-line construction through commercial process validation, purification, viral clearance and fill, plus an allogeneic cell-therapy centre of excellence and a strong regulatory-inspection record.
Runs a roughly 24,000 m2 sterile fill-finish CDMO site at 31 Joo Koon Circle (with reserved expansion of a further ~14,000 m2), offering a high-speed, fully automated aseptic liquid-vial filling line with single-use formulation up to 1,000 litres for both small- and large-molecule products, and reserved future capacity for lyophilised vials, prefilled syringes and cartridges.
Building a roughly US$1.4 billion integrated CRDMO on a 13.5-hectare Tuas site adding 120,000 litres of biologics capacity and about 1,500 jobs, offering end-to-end drug-substance and drug-product (fill-finish) services across monoclonal antibodies, bispecifics and recombinant proteins on single-use technology.
Building a ~22,000 m2 Tuas facility for ADC and bioconjugate drug substance up to 2,000 litres plus drug-product lyophilisation engineered for over 8 million vials a year, with onsite MSAT and QC.
ENQUIRE
Not sure which supplier?
Tell the Singapore Industry Index what you need — this enquiry is tagged to Contract development and manufacturing (CDMO) — and we'll point you to the companies on the record that do it. To reach one company directly, enquire from its profile above.
Your enquiry is on its way.
The Singapore Industry Index has it and will be in touch.